Onyx Pharmaceuticals and the UCSF Helen Diller Family Comprehensive Cancer
Center Announce Oncology Innovation Alliance
Strategic Alliance Focused on Advancing Drug Discovery and
SOUTH SAN FRANCISCO, CA and SAN FRANCISCO, CA -- (Marketwired) --
06/03/13 -- Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX) and the
University of California, San Francisco (UCSF) Helen Diller Family
Comprehensive Cancer Center today announced the formation of the
Oncology Innovation Alliance (OIA), a public-private partnership
focusing on the discovery and development of novel therapies and
their potential role in treating various types of hematologic cancers
and solid tumors.
"This collaboration will leverage expertise across UCSF and Onyx to
further our collective understanding of cancer and hopefully
translate scientific research rapidly from the laboratory to the
clinic and, ultimately, to patients," said Pablo J. Cagnoni, M.D.,
Executive Vice President, Global Research & Development and Technical
Operations at Onyx Pharmaceuticals. "The UCSF Helen Diller Family
Comprehensive Cancer Center is a recognized leader in oncology
research and patient care, and Onyx is committed to forming strategic
alliances that encourage innovation and the advancement of new
treatments for patients."
The alliance aims to transform cancer care by harnessing the
expertise in fundamental science and medicine at both UCSF and Onyx
to address the full continuum of that care, from prediction and
diagnosis to new therapies and post-treatment monitoring, to identify
opportunities to improve the patient experience and outcomes.
The partnership will focus on drug discovery and development, and
seeks to advance the broader scope of patient care while contributing
to the biological understanding of hematologic malignancies and solid
tumors, discovering novel drug targets, identifying potential
biomarkers to support patient selection and implementing innovative
clinical development approaches.
"UCSF and Onyx share a vision of transforming care for patients with
cancer, so we can precisely diagnose, treat and possibly even prevent
cancer from occurring," said Jeffrey Bluestone, PhD, Executive Vice
Chancellor and Provost at UCSF. "Our goal is to create an umbrella
partnership that enables us to work together to better understand the
cascade of events within a cell that leads to disease, and find
innovative ways to use that knowledge to diagnose and treat patients
far more precisely than we can today."
A joint steering committee comprised of representatives from Onyx and
UCSF will provide oversight of the alliance. The term of the
agreement extends for three years. Financial terms of the
collaboration were not disclosed.
About Onyx Pharmaceuticals, Inc.
Based in South San Francisco,
California, Onyx Pharmaceuticals, Inc. is a global biopharmaceutical
company engaged in the development and commercialization of
innovative therapies for improving the lives of people with cancer.
The company is focused on developing novel medicines that target key
molecular pathways. For more information about Onyx, visit the
company's website at www.onyx.com. Onyx Pharmaceuticals is on
Twitter. Sign up to follow our Twitter feed @OnyxPharm at
The University of California, San Francisco (UCSF) is a
leading university dedicated to promoting health worldwide through
advanced biomedical research, graduate-level education in the life
sciences and health professions, and excellence in patient care. For
further information, please visit www.ucsf.edu.
The Office of Innovation, Technology and Alliances (ITA) coordinates
UCSF's efforts in forging collaborations that translate cutting-edge
UCSF research into therapies and products that directly benefit
patients worldwide. The office oversees technology transfer,
entrepreneurship and innovative research alliances with commercial,
non-profit, and government organizations. UCSF is among the world's
top recipients of U.S. biotechnology patents and has consistently
ranked first in the UC system as measured by annual license income,
total patents, and total licenses. Its commitment to finding
innovative ways to bridge the gap between basic research and
real-world applications while protecting academic freedom is
reflected in the breadth of research partnerships UCSF has with
companies in pharmaceuticals, biotech, high tech and other innovative
This news release contains
"forward-looking statements" of Onyx within the meaning of the
federal securities laws. These forward-looking statements include
without limitation, statements regarding the progress and results of
the clinical development, safety, regulatory processes,
commercialization efforts or commercial potential of Kyprolis
(carfilzomib) or oprozomib. These statements are subject to risks and
uncertainties that could cause actual results and events to differ
materially from those anticipated, including risks related to the
development and commercialization of pharmaceutical products. Any
statements contained in this press release that are not statements of
historical fact may be deemed to be forward-looking statements.
Reference should be made to Onyx's Quarterly Report on Form 10-Q for
the quarterly period ended March 31, 2013, filed with the Securities
and Exchange Commission under the heading "Risk Factors" for a more
detailed description of such factors. Readers are cautioned not to
place undue reliance on these forward-looking statements that speak
only as of the date of this release. Onyx undertakes no obligation to
update publicly any forward-looking statements to reflect new
information, events, or circumstances after the date of this release
except as required by law.
Senior Director, Investor Relations
Senior Director, Corporate Communications
Assistant News Director
Press spacebar to pause and continue. Press esc to stop.